Welcome to our dedicated page for Compass Pathways news (Ticker: CMPS), a resource for investors and traders seeking the latest updates and insights on Compass Pathways stock.
COMPASS Pathways plc reports biotechnology developments centered on COMP360, its proprietary synthetic psilocybin treatment candidate for serious mental health conditions, with treatment-resistant depression as the primary disclosed focus. News commonly covers clinical data, FDA and UK regulatory designations, NDA submission and review activity, and the company's work on delivery models for psychedelic treatment in clinical settings.
Recurring updates also include financial results and business highlights, investor conference participation, collaborations with psychiatry and care-delivery organizations, healthcare provider training initiatives, and equity compensation actions under Nasdaq rules. As an ADR-listed issuer, CMPS news can reflect parent-company operating updates and American Depositary Share-related corporate actions.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
The global psychedelic drugs market witnessed growth, expanding from $4.2 billion in 2022 to $4.83 billion in 2023, at a CAGR of 14.9%. This market is poised to reach $8.31 billion by 2027, with a CAGR of 14.5%. The report comprises essential market insights, detailing a variety of players including Johnson & Johnson, Pfizer, COMPASS Pathways PLC (CMPS), and others. Mental health conditions, particularly depression and PTSD, are major focus areas driving growth. Additionally, the introduction of innovative treatments such as nasal sprays is becoming a trend. The report also discusses the impact of global factors like COVID-19, inflation, and geopolitical issues on the market expansion.
COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company, will present at the 22nd Annual Needham Virtual Healthcare Conference on April 19, 2023, at 9:30 am ET. The presentation will be accessible via a live audio webcast on the company’s website, with a replay available for 30 days afterward.
COMPASS focuses on accelerating patient access to innovative mental health solutions, particularly through its psilocybin therapy, COMP360, which has received Breakthrough Therapy designation from the FDA and ILAP designation in the UK for treatment-resistant depression (TRD). The company is conducting the largest-ever randomized, controlled, double-blind psilocybin therapy clinical program for TRD, following a successful phase 2b study that demonstrated significant improvements in depressive symptoms.
COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company, announced management participation in three significant events. These include:
- Cowen 43rd Annual Health Care Conference on March 6, 2023, at 12:50 pm ET
- Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023, at 10:00 am ET
- Loop Capital Conference on March 14, 2023
Live webcasts will be available on their investors’ page, with replays for 30 days post-event. COMPASS focuses on providing innovative treatment options, notably their psilocybin therapy COMP360, which has been designated as a Breakthrough Therapy by the FDA and targets treatment-resistant depression.
COMPASS Pathways plc (Nasdaq: CMPS) has made significant progress with its COMP360 psilocybin therapy. The Phase 3 pivotal program for treatment-resistant depression (TRD) includes two trials, with the first one (COMP 005) expecting data by summer 2024 and the second (COMP 006) by mid-2025. The company's cash position stands at $143.2 million as of December 31, 2022, despite a net loss of $91.5 million for the year. R&D expenses increased to $65.1 million for 2022, reflecting ongoing clinical investigations. Financial guidance for Q1 2023 indicates an operating cash outflow of $24-$32 million.